AKTX insider trading
NasdaqCM HealthcareAkari Therapeutics Plc: insider trade history from SEC Form 4 filings.
About Akari Therapeutics Plc
Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, colon, and prostate. Its payloads include PH5, which inhibits DNA mismatch repair (MMR) and DNA damage response (DDR) to generate neoepitopes, and PH6, which inhibits DNA transcription in cancer cells and co-opted immune cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Boston, Massachusetts.
Company website: www.akaritx.com
AKTX insider activity at a glance
FilingIQ tracks 56 insider transactions for AKTX in filings since Sep 22, 2015. The most recent transaction is dated Sep 29, 2026.
Across the full history, 8 open-market purchases
and 0 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on AKTX insider trades is 52.6/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest AKTX Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for AKTX?
- FilingIQ tracks 56 Form 4 insider transactions for AKTX (Akari Therapeutics Plc), covering filings from Sep 22, 2015 onwards. 3 of those are dated within the last 90 days.
- Are AKTX insiders net buyers or net sellers?
- Across the full Form 4 history for AKTX, 8 transactions (14%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does AKTX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is AKTX in?
- Akari Therapeutics Plc (AKTX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $11.75M.
Methodology & sources
Every AKTX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.